Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial

Recent international guidelines have lowered recommended target levels of low-density lipoprotein cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascular events (MACE). However, uncertainty persists whether additional benefit results from achieved LDL-C levels below the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gregory G., Gabriel Steg, Philippe, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Kim, Yong-Un, Li, Qian H., Manvelian, Garen, Pordy, Robert, Sourdille, Timothée, White, Harvey D., Szarek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969166/
https://www.ncbi.nlm.nih.gov/pubmed/33438437
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.049447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969166/
https://www.ncbi.nlm.nih.gov/pubmed/33438437
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.049447

Ejemplares similares